Changing the time intervals between cisplatin cycles alter its ototoxic side effect.

Area of Science:

• Ototoxicity research
• Cancer chemotherapy side effects
• Auditory neuroscience

Background:

• Cisplatin is a widely used chemotherapy drug.
• Ototoxicity, or hearing loss, is a common and serious side effect of cisplatin.
• Current strategies to minimize cisplatin ototoxicity include dose adjustments and early identification of hearing loss.

Purpose of the Study:

• To investigate the impact of varying inter-cycle intervals of cisplatin administration on ototoxicity.
• To determine if extending the rest periods between cisplatin cycles can reduce hearing damage.

Main Methods:

• CBA/CaJ mice received a cumulative dose of 48 mg/kg cisplatin in three cycles.
• Cycles were separated by 10, 17, or 87 days.
• Ototoxicity was assessed via auditory brainstem response threshold shifts and quantification of outer hair cell loss.

Main Results:

• Longer intervals between cisplatin cycles resulted in significantly lower auditory threshold shifts.
• Increased rest periods between doses led to reduced outer hair cell lesions in the cochlea.
• The findings suggest a dose-interval relationship in cisplatin-induced ototoxicity.

Conclusions:

• Increasing the rest intervals between cisplatin cycles is an effective strategy for reducing ototoxicity.
• Slowing down cisplatin administration by extending inter-cycle breaks can mitigate hearing loss and cochlear damage.
• Further studies are required to optimize these dosing schedules and evaluate their impact on anti-tumor efficacy.